Key result
Three-dose inactivated rotavirus vaccine elicits high IgG titers and neutralizing activity in guinea pigs.
Why the study?
Lower efficacy of live oral rotavirus vaccines among infants in low income countries and safety concerns such as rare severe intussusception motivated development of an inactivated rotavirus vaccine.
Does an inactivated rotavirus vaccine (CDC-9 strain) elicit an immune response in guinea pigs?
Does an inactivated rotavirus vaccine (CDC-9 strain) elicit an immune response in guinea pigs?
The candidate inactivated rotavirus vaccine CDC-9 elicits a strong heterotypic antibody response and high IgG avidity in a guinea pig model, suggesting potential as a safer alternative to live oral vaccines.
Supports CDC-9 advancement to human trials; leaves open clinical safety and efficacy.
To improve lower efficacy among infants in low income countries and the safety (e.g., rare but severe intussusception) of live oral rotavirus vaccines, we have developed CDC-9 strain with G1P[8] specificity as a candidate inactivated rotavirus vaccine (IRV). This IRV of 3 doses elicits high titers of IgG, neutralizing activity to homotypic and heterotypic human strains and IgG avidity in guinea pigs, thus is a promising alternative to enhance global immunization against rotavirus in children.
No takes yet. Share an insight, caveat, or question.
Velásquez et al. (2015) studied Rotavirus. CDC-9 strain candidate inactivated rotavirus vaccine (IRV) was evaluated on IgG titers, neutralizing activity, and IgG avidity. A 3-dose regimen of the candidate inactivated rotavirus vaccine (CDC-9 strain) elicited high titers of IgG, neutralizing activity, and IgG avidity in guinea pigs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: